A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Recruiting

Phase 4 Results N/A

Summary of Purpose

This is a prospective and open label study that aims to enroll approximately 1200 patients with non-valvular atrial fibrillation (NVAF) not previously treated with Pradaxa® and free of gastrointestinal symptoms (GIS) for at least 12 months prior to enrolment. Approximately 60 - 80 sites in North America will be recruited. Patients who report GIS during the 3 month treatment period will be randomized to one of...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 17 April 2013.

1 Dec 2011 12 Dec 2011 1 Sep 2013 1 Sep 2013 1 Apr 2013 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Open Label
  • Purpose: Prevention
  • Intervention: Parallel Assignment

Contacts